StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1419.HK$0.78+0.00%
Fair $0.78+0.0%

1419.HK

Human Health Holdings Limited

Healthcare / Medical Care FacilitiesHKSE

$0.78

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.78Fund rank 32/100 · Data gapFallback financials|
SA 46/C
F-Score: 8/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $90.8M · quality 57.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 34/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is 3.4%, below the 5% threshold
Thesis & Journal · 1419.HKLocal privado en este navegador · Human Health Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$296M

P/E

11.1x

↓

EV/EBITDA

-0.1x

↓

ROE

3.4%

↑

Gross Margin

45.8%

↓

Debt/Equity

0.17

↓
52-Week Range$1
$1$1

TradingView lightweight chart

1419.HK price, volumen y niveles de valoración

Último $0.780Periodo -60.8%
Fair value: $0.780

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-16.9%

FCF CAGR

-25.5%

FCF margin

14.1%

FCF / Net income

3.45x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $644.4M · net income $26.3M · FCF $90.8M

2022-FY → 2025-FY

Gross margin

45.8%-13.0% pts

Operating margin

3.7%-33.8% pts

Net margin

4.1%-29.4% pts

FCF margin

14.1%-5.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$644.4M$644.4M$590.8M$1.00B$1.12B
Net Income$26.3M$26.3M$24.2M$180.8M$375.3M
EBITDA$104.2M$104.2M$102.8M$321.9M$511.3M
EPS0.070.070.060.480.99
Gross Margin45.8%45.8%45.7%59.2%58.8%
Operating Margin3.7%3.7%1.1%24.6%37.5%
Net Margin4.1%4.1%4.1%18.1%33.5%
Balance Sheet
Debt/Equity0.170.170.190.230.25
Current Ratio3.143.14———
Cash Flow
Free Cash Flow$90.8M$90.8M$-26.3M$580.2M$219.3M
Returns
ROE3.4%3.4%3.2%22.4%50.6%
Valuation
P/E11.1411.1416.723.911.70
EV/EBITDA-0.09-0.090.610.771.09
P/B0.380.380.530.870.86
Growth & Yield
Revenue Growth9.1%9.1%-41.0%-10.7%—
EPS Growth7.8%7.8%-86.6%-51.9%—
Dividend Yield3.9%3.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

0.1%

fácil

EPS terminal req.

$0.07

Spread vs growth

7.7%

5Y implied EPS CAGR

3.9%

fácil

EPS terminal req.

$0.08

Spread vs growth

3.9%

10Y implied EPS CAGR

6.9%

razonable

EPS terminal req.

$0.13

Spread vs growth

0.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.1%

Total return

+0.1%

Start / end P/E

12.7x → 11.3x

EPS bridge

0.06 → 0.07

Residual

-0.8%

EPS growth+7.8%
Multiple rerating-10.7%
Dividend+3.9%
Residual / FX / buybacks / cross-term-0.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.